



an Open Access Journal by MDPI

Innovations in Soft Tissue Sarcoma Diagnosis and Treatment

Guest Editors

Dr. Erlinda M. Gordon, Dr. Sant P. Chawla, Dr. Frederick L. Hall

Deadline

31 January 2023







an Open Access Journal by MDPI

Innovations in Soft Tissue Sarcoma Diagnosis and Treatment

Guest Editors:

Dr. Erlinda M. Gordon

Sarcoma Oncology Research Center, Santa Monica, CA 90403, USA

egordon@sarcomaoncology.com

Dr. Sant P. Chawla

Sarcoma Oncology Research Center, Santa Monica, CA 90403, USA

santchawla@ sarcomaoncology.com

Dr. Frederick L. Hall

Sarcoma Oncology Research Center, Santa Monica, CA 90403, USA

doctor.frederick.hall@gmail.com

Deadline for manuscript submissions:

31 January 2023

Message from the Guest Editors

Dear Colleagues,

Recent advances in genetic screening, molecular profiling, targeted therapy, gene therapy and immunotherapy for soft tissue sarcomas (STS) have evoked increasing optimism in the medical and scientific community. Hence, it is time to reflect on the many faces of STS and current innovations in its diagnosis and treatment. STS is a rare cancer involving mesodermal tissues. Surgical resection is the standard of care for localized disease, but its recurrence rate is high and the prognosis for advanced STS is poor, with a median survival of 8–13 months.

This Special Issue entitled "Innovations in Soft Tissue Sarcoma Diagnosis and Treatment" will include review articles, original clinical and translational research articles that are hypothesis-generating toward the development of precision medicine for STS.

Dr. Erlinda M. Gordon Dr. Sant P. Chawla Dr. Frederick L. Hall *Guest Editors*









an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q2 (Oncology)

Contact Us